Development of an Assay for the Early Detection of Ovarian Cancer

卵巢癌早期检测检测方法的开发

• 批准号: 7730281
• 负责人: LAURENT BRARD
• 金额: $ 43.71万
• 依托单位: WOMEN AND INFANTS HOSPITAL-RHODE ISLAND
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2014-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7730281
• 关键词: Address; Affect; Atherosclerosis; Basic Science; Binding; Biological; Biological Assay; Biological Markers; Biomimetics; Blood; Blood specimen; CA-125 Antigen; Calibration; Clinical; Communities; Complex; Detection; Development; Diagnosis; Disease; Early Diagnosis; Etiology; Evaluation; Feedback; Fluorescence; Fluorescence Spectroscopy; Goals; Grant; Growth Factor; Gynecologic Oncologist; Gynecology; Head; Health; Hospitals; Human; Human Resources; Imaging Techniques; Indicators and Reagents; Infant; Institution; Investigation; Lead; Lysophospholipids; Malignant Neoplasms; Malignant neoplasm of ovary; Methods; Micelles; Molecular Target; Monitor; Nature; Operative Surgical Procedures; Organic Chemistry; Ovary; Pelvis; Pharmacologic Substance; Phase; Phospholipids; Physicians; Physiological; Plasma; Polymers; Population Study; Postdoctoral Fellow; Preparation; Property; Proteins; Quality Control; Reagent; Recurrence; Reporting; Research; Research Infrastructure; Research Personnel; Sampling; Scheme; Scientist; Screening for Ovarian Cancer; Screening procedure; Sensitivity and Specificity; Serum; Solid; Staging; Structure; Surgeon; Survival Rate; Techniques; Training; Translational Research; Triage; Ultrasonography; United States National Academy of Sciences; Universities; Urine; Validation; Vascular Diseases; Woman; assay development; base; cancer cell; cancer diagnosis; design; effective therapy; enzyme activity; high risk; imprint; improved; inorganic phosphate; lysophosphatidic acid; medical schools; novel strategies; oncology; point of care; programs; public health relevance; user-friendly

DESCRIPTION (provided by applicant): This proposal addresses the lack of simple and reliable methods for the early detection of ovarian cancer. The design and creation of relatively inexpensive and robust materials for the routine LPA (lysophosphatidic acid) screening are described. The proposed methods are designed for eventual use by minimally-trained personnel. The project brings together experts in chemosensing, materials fabrication, fluorescence spectroscopy and gynecological oncology. LPA is currently a controversial biomarker for early stage ovarian cancer. The proposed efforts will, at the very least, enable further LPA research and also embody a unique perspective to help answer significant questions concerning LPA's relevance in pelvic mass triaging, ovarian cancer diagnosis, and monitoring for disease recurrence. In addition, LPA-associated enzyme activity screening is needed for pharmaceutical development, and LPA monitoring is also of apparent clinical utility in atherosclerosis and related vascular disorders. Thus, the study proposed would clearly produce findings of significance to the biomedical community. There are three Specific Aims: Specific Aim 1. The investigation of selective chemosensors for LPA. The unique structure of LPA will lead to the design of highly selective, biomimetic binding and sensing reagents. Specific Aim 2. The use of tailored solid supports to enhance selectivity and sensitivity for LPA in biological media. LPA-selective polymeric materials will be used to pre-concentrate LPA and simplify the analytical matrix prior to analysis by the selective indicator reagents described in Aim 1. Specific Aim 3. Methods validation using human blood and urine samples. The goals of this Specific Aim are to validate (i) the proposed assay for LPA via comparison to established techniques, and (ii) LPA as a biomarker for triaging women diagnosed with a pelvic mass. PUBLIC HEALTH RELEVANCE: Ovarian cancer is one of the most lethal cancers affecting women. This is due to the inability to detect it while still localized to the ovaries. Early detection would result in a 90 % survival rate. LPA, a currently controversial biomarker for ovarian cancer diagnosis, is the subject of this application. A simple new method for detecting LPA and a fresh approach to validating LPA's reliability as an accurate biomarker would emanate from the proposed studies.

描述（由申请人提供）：该提案解决了缺乏早期发现卵巢癌的简单可靠方法。描述了常规LPA（溶血磷脂酸）筛选的相对便宜且可靠的材料的设计和创建。该建议的方法旨在最终使用最少训练的人员使用。该项目汇集了化学传感，材料制造，荧光光谱和妇科肿瘤学方面的专家。 LPA目前是早期卵巢癌的有争议的生物标志物。拟议的努力至少将实现进一步的LPA研究，并体现出独特的观点，以帮助回答有关LPA在骨盆大质量分域，卵巢癌诊断和监测疾病复发中相关的重要问题。此外，药物开发需要与LPA相关的酶活性筛查，而LPA监测在动脉粥样硬化和相关血管疾病中也显然具有临床实用性。因此，提出的研究清楚地将对生物医学群落产生意义。有三个特定的目的：特定目标1。对LPA的选择性化学传感器的研究。 LPA的独特结构将导致高度选择性，仿生结合和传感试剂的设计。特定的目标2。使用定制的固体支持来增强生物介质中LPA的选择性和灵敏度。 LPA选择性聚合物材料将用于预浓缩LPA并通过AIM 1中描述的选择性指标试剂进行分析之前简化分析矩阵。特定的目标3。使用人血和尿液样品验证方法。该特定目的的目标是通过与既定技术进行比较来验证（i）LPA的拟议测定法，以及（ii）LPA作为诊断为骨盆质量的妇女的生物标志物。公共卫生相关性：卵巢癌是影响妇女的最致命的癌症之一。这是由于无法在仍在卵巢的同时检测到它。早期检测将导致90％的存活率。 LPA是目前有争议的卵巢癌诊断生物标志物，是该应用的主题。一种用于检测LPA的简单新方法和一种验证LPA可靠性作为准确的生物标志物的新方法，将从拟议的研究中散发出来。